Recent studies have reported a significant increase in risk of CRC and colorectal adenomas, respectively, among patients with type 2 diabetes on insulin therapy compared to non-insulin users (Chung et al., 2008[7]; Yang et al., 2004[40]), but the data are still conflicting. The gene discussed is INS; the disease is type 2 diabetes mellitus.